Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovant Says Antibiotic Effective for Pneumonia; Transfers China Rights to Sumitomo

publication date: May 27, 2021

Sinovant Sciences, a Shanghai biopharma, reported positive topline results from its Phase III bridging study of lefamulin in China adults with community acquired bacterial pneumonia (CABP). The trial showed lefamulin was non-inferior to IV/oral moxifloxacin in patients with CABP. In 2017, Sinovant acquired China rights to the anti-infective from Nabriva, a Vienna company, in a $95 million agreement. Sinovant will transfer the China rights for lefamulin to Sumitomo Pharma (Suzhou) along with rights to three other Sinovant candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021